Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04971785 · ClinicalTrials.gov registry record · Phase 2
Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)
A Phase 2 study, sponsored by Gilead Sciences.
- Completed
- Registry status
- Phase 2
- Development phase
- 457
- Enrollment target
NCT04971785 is a Phase 2 study that has completed, run by Gilead Sciences. The registered enrollment target is 457 participants.
The verdict
NCT04971785, a Phase 2 study, has completed, sponsored by Gilead Sciences.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 457 participants
- Enrollment target
Study Summary
The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
Interventions
- DRUG Semaglutide (SEMA)
- DRUG Cilofexor (CILO)/Firsocostat (FIR)
- DRUG PTM SEMA
- DRUG PTM CILO/FIR
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 457 participants |
| Start Date | 2021-08-09 |
| Est. Completion | 2024-12-09 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04971785
The ClinicalTrials.gov registry entry for NCT04971785 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 457 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Gilead Sciences, which has 504 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Semaglutide (SEMA) is the first listed.
NCT04971785 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04971785 about?
NCT04971785 is a clinical study titled "Study of Semaglutide, and Cilofexor/Firsocostat, Alone and in Combination, in Adults With Cirrhosis Due to Nonalcoholic Steatohepatitis (NASH)". The goal of this clinical study is to understand whether the study drugs, semaglutide (SEMA) with the fixed-dose combination (FDC) of cilofexor/firsocostat (CILO/FIR), cause fibrosis improvement and Nonalcoholic Steatohepatitis (NASH) resolution in participants with cirrhosis due to NASH.
What is the current status of trial NCT04971785?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 457 participants. The study started on 2021-08-09. Estimated completion is 2024-12-09.
What interventions are being tested in trial NCT04971785?
The interventions under investigation include: Semaglutide (SEMA) (DRUG), Cilofexor (CILO)/Firsocostat (FIR) (DRUG), PTM SEMA (DRUG), PTM CILO/FIR (DRUG).
Who is sponsoring clinical trial NCT04971785?
This trial is sponsored by Gilead Sciences, which has 504 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.